Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1957 1
1958 1
1965 1
1966 1
1967 1
1969 1
1970 1
1971 2
1972 4
1973 4
1974 10
1975 8
1976 25
1977 27
1978 19
1979 38
1980 40
1981 30
1982 30
1983 16
1984 32
1985 21
1986 32
1987 30
1988 37
1989 43
1990 45
1991 42
1992 42
1993 57
1994 52
1995 62
1996 72
1997 66
1998 63
1999 89
2000 90
2001 104
2002 93
2003 95
2004 104
2005 119
2006 150
2007 142
2008 146
2009 174
2010 150
2011 187
2012 216
2013 226
2014 238
2015 267
2016 260
2017 236
2018 261
2019 288
2020 338
2021 324
2022 282
2023 301
2024 134

Text availability

Article attribute

Article type

Publication date

Search Results

5,338 results

Results by year

Filters applied: . Clear all
Page 1
Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy.
León-Castillo A, de Boer SM, Powell ME, Mileshkin LR, Mackay HJ, Leary A, Nijman HW, Singh N, Pollock PM, Bessette P, Fyles A, Haie-Meder C, Smit VTHBM, Edmondson RJ, Putter H, Kitchener HC, Crosbie EJ, de Bruyn M, Nout RA, Horeweg N, Creutzberg CL, Bosse T; TransPORTEC consortium. León-Castillo A, et al. J Clin Oncol. 2020 Oct 10;38(29):3388-3397. doi: 10.1200/JCO.20.00549. Epub 2020 Aug 4. J Clin Oncol. 2020. PMID: 32749941 Free PMC article.
PURPOSE: The randomized Adjuvant Chemoradiotherapy Versus Radiotherapy Alone in Women With High-Risk Endometrial Cancer (PORTEC-3) trial investigated the benefit of combined adjuvant chemotherapy and radiotherapy (CTRT) versus radiotherapy alone (RT) f …
PURPOSE: The randomized Adjuvant Chemoradiotherapy Versus Radiotherapy Alone in Women With High-Risk Endometrial Cancer …
Uterine serous carcinoma.
Bogani G, Ray-Coquard I, Concin N, Ngoi NYL, Morice P, Enomoto T, Takehara K, Denys H, Nout RA, Lorusso D, Vaughan MM, Bini M, Takano M, Provencher D, Indini A, Sagae S, Wimberger P, Póka R, Segev Y, Kim SI, Candido Dos Reis FJ, Lopez S, Mariani A, Leitao MM Jr, Raspagliesi F, Panici PB, Di Donato V, Muzii L, Colombo N, Scambia G, Pignata S, Monk BJ. Bogani G, et al. Gynecol Oncol. 2021 Jul;162(1):226-234. doi: 10.1016/j.ygyno.2021.04.029. Epub 2021 Apr 30. Gynecol Oncol. 2021. PMID: 33934848 Free PMC article. Review.
Serous endometrial cancer represents a relative rare entity accounting for about 10% of all diagnosed endometrial cancer, but it is responsible for 40% of endometrial cancer-related deaths. ...To date, the combination of pembrolizumab and …
Serous endometrial cancer represents a relative rare entity accounting for about 10% of all diagnosed endometrial ca …
Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study.
O'Malley DM, Bariani GM, Cassier PA, Marabelle A, Hansen AR, De Jesus Acosta A, Miller WH Jr, Safra T, Italiano A, Mileshkin L, Xu L, Jin F, Norwood K, Maio M. O'Malley DM, et al. J Clin Oncol. 2022 Mar 1;40(7):752-761. doi: 10.1200/JCO.21.01874. Epub 2022 Jan 6. J Clin Oncol. 2022. PMID: 34990208 Free PMC article. Clinical Trial.
We report efficacy and safety outcomes for patients with MSI-H/dMMR endometrial cancer enrolled in KEYNOTE-158. METHODS: Eligible patients from cohorts D (endometrial cancer, regardless of MSI-H/dMMR status) and K (any MSI-H/dMMR solid tumor, except co …
We report efficacy and safety outcomes for patients with MSI-H/dMMR endometrial cancer enrolled in KEYNOTE-158. METHODS: Eligi …
Brachytherapy: An overview for clinicians.
Chargari C, Deutsch E, Blanchard P, Gouy S, Martelli H, Guérin F, Dumas I, Bossi A, Morice P, Viswanathan AN, Haie-Meder C. Chargari C, et al. CA Cancer J Clin. 2019 Sep;69(5):386-401. doi: 10.3322/caac.21578. Epub 2019 Jul 30. CA Cancer J Clin. 2019. PMID: 31361333 Free article. Review.
Many patients require brachytherapy as either primary treatment or as part of their oncologic care. On the basis of high-level evidence from randomized controlled trials, brachytherapy is mainly indicated: 1) as standard in combination with chemoradiation in patients with …
Many patients require brachytherapy as either primary treatment or as part of their oncologic care. On the basis of high-level evidence from …
Immune checkpoint blockades in gynecological cancers: A review of clinical trials.
Peng H, He X, Wang Q. Peng H, et al. Acta Obstet Gynecol Scand. 2022 Sep;101(9):941-951. doi: 10.1111/aogs.14412. Epub 2022 Jun 25. Acta Obstet Gynecol Scand. 2022. PMID: 35751489 Free PMC article. Review.
Six phase III clinical trials have reported their results of primary outcomes, and a total of 25 phase II clinical trials have been completed. ...Based on these findings, pembrolizumab was approved by the Food and Drug Administration and European Medicines Agency as …
Six phase III clinical trials have reported their results of primary outcomes, and a total of 25 phase II clinical trials have …
PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer.
van den Heerik ASVM, Horeweg N, Nout RA, Lutgens LCHW, van der Steen-Banasik EM, Westerveld GH, van den Berg HA, Slot A, Koppe FLA, Kommoss S, Mens JWM, Nowee ME, Bijmolt S, Cibula D, Stam TC, Jurgenliemk-Schulz IM, Snyers A, Hamann M, Zwanenburg AG, Coen VLMA, Vandecasteele K, Gillham C, Chargari C, Verhoeven-Adema KW, Putter H, van den Hout WB, Wortman BG, Nijman HW, Bosse T, Creutzberg CL. van den Heerik ASVM, et al. Int J Gynecol Cancer. 2020 Dec;30(12):2002-2007. doi: 10.1136/ijgc-2020-001929. Epub 2020 Oct 12. Int J Gynecol Cancer. 2020. PMID: 33046573 Free PMC article.
BACKGROUND: Vaginal brachytherapy is currently recommended as adjuvant treatment in patients with high-intermediate risk endometrial cancer to maximize local control and has only mild side effects and no or limited impact on quality of life. ...TRIAL DESIGN: …
BACKGROUND: Vaginal brachytherapy is currently recommended as adjuvant treatment in patients with high-intermediate risk endometrial …
Long-term hormone therapy for perimenopausal and postmenopausal women.
Marjoribanks J, Farquhar C, Roberts H, Lethaby A, Lee J. Marjoribanks J, et al. Cochrane Database Syst Rev. 2017 Jan 17;1(1):CD004143. doi: 10.1002/14651858.CD004143.pub5. Cochrane Database Syst Rev. 2017. PMID: 28093732 Free PMC article. Review.
We searched the registers of ongoing trials and reference lists provided in previous studies and systematic reviews. SELECTION CRITERIA: We included randomised double-blinded studies of HT versus placebo, taken for at least 1 year by perimenopausal or postmenopausal women. …
We searched the registers of ongoing trials and reference lists provided in previous studies and systematic reviews. SELECTION CRITERIA: We …
Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Lancet Oncol. 2022 Mar;23(3):382-392. doi: 10.1016/S1470-2045(21)00758-0. Epub 2022 Feb 3. Lancet Oncol. 2022. PMID: 35123662 Free PMC article.
METHODS: We did a meta-analysis of individual patient data from randomised trials comparing aromatase inhibitors (anastrozole, exemestane, or letrozole) versus tamoxifen for 3 or 5 years in premenopausal women with ER-positive breast cancer receiving ovarian suppression (g …
METHODS: We did a meta-analysis of individual patient data from randomised trials comparing aromatase inhibitors (anastrozole, exemes …
Short-term and long-term effects of tibolone in postmenopausal women.
Formoso G, Perrone E, Maltoni S, Balduzzi S, Wilkinson J, Basevi V, Marata AM, Magrini N, D'Amico R, Bassi C, Maestri E. Formoso G, et al. Cochrane Database Syst Rev. 2016 Oct 12;10(10):CD008536. doi: 10.1002/14651858.CD008536.pub3. Cochrane Database Syst Rev. 2016. PMID: 27733017 Free PMC article. Review.
Other outcomesEvidence on other outcomes was of low or very low quality, with no clear evidence of any differences between the groups. Effect estimates were as follows: Endometrial cancer: OR 2.04, 95% CI 0.79 to 5.24; nine RCTs; 8504 women; I(2) = 0%. ...Evidence w …
Other outcomesEvidence on other outcomes was of low or very low quality, with no clear evidence of any differences between the groups. Effec …
Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial.
Burn J, Sheth H, Elliott F, Reed L, Macrae F, Mecklin JP, Möslein G, McRonald FE, Bertario L, Evans DG, Gerdes AM, Ho JWC, Lindblom A, Morrison PJ, Rashbass J, Ramesar R, Seppälä T, Thomas HJW, Pylvänäinen K, Borthwick GM, Mathers JC, Bishop DT; CAPP2 Investigators. Burn J, et al. Lancet. 2020 Jun 13;395(10240):1855-1863. doi: 10.1016/S0140-6736(20)30366-4. Lancet. 2020. PMID: 32534647 Free PMC article. Clinical Trial.
BACKGROUND: Lynch syndrome is associated with an increased risk of colorectal cancer and with a broader spectrum of cancers, especially endometrial cancer. In 2011, our group reported long-term cancer outcomes (mean follow-up 55.7 months [SD 31.4]) for participants …
BACKGROUND: Lynch syndrome is associated with an increased risk of colorectal cancer and with a broader spectrum of cancers, especially e …
5,338 results